Changes in Beneficial Ownership · 4
TScan Therapeutics, Inc.
TCRXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-10-01
- Issuer
- TScan Therapeutics, Inc.
- Issuer CIK
- 0001783328
- Trading symbol
- TCRX
Reporting owner 1
- Name
- MacBeath Gavin
- Reporting owner CIK
- 0001738082
- Relationship
- Director · Officer
- Officer title
- Chief Executive Officer
- Address
- C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM, MA, 02451
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Voting Common Stock | 2026-10-01 | A · Form 4[F1] | 1,000,000 | A | 0.00 | 1,049,767 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- 25% of the restricted stock units ("RSUs") shall vest on September 30, 2028, with the remaining 75% of the RSUs vesting on the earlier of (i) reporting of completion of the pivotal trial of TSC-101, or (ii) September 30, 2030, subject to continued service with the Issuer through the applicable vesting dates and the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan and the applicable award agreement.↩ 1
Signature 1
- Signed
- /s/ Zoran Zdraveski, Attorney-in-Fact
- Date
- 2026-10-02
Company context
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company is advancing two therapeutics candidates through IND-enabling studies to treat solid tumors using in vivo-engineered TCR-T cells. In addition, the Company is seeking partnerships for its heme and autoimmune programs. To learn more, visit www.tscan.com and connect with us on LinkedIn and X.
Current securities
Recent company filings
- 4 filingOct 2, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 30, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 11, 2026
- Costs Associated with Exit or Disposal Activities · Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure · Other EventsSep 2, 2026
- Termination of a Material Definitive AgreementAug 18, 2026